Leon O. Moulder Jr - Sep 18, 2024 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Signature
By: /s/ Chase Jayasekera, Attorney-in-Fact
Stock symbol
ZBIO
Transactions as of
Sep 18, 2024
Transactions value $
$360,820
Form type
4
Date filed
9/20/2024, 06:34 PM
Previous filing
Sep 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZBIO Common Stock Purchase $179K +10K +0.61% $17.91 1.66M Sep 18, 2024 See Footnote F1, F2
transaction ZBIO Common Stock Purchase $89.5K +5K +0.3% $17.89 1.67M Sep 19, 2024 See Footnote F2, F3
transaction ZBIO Common Stock Purchase $42.3K +2.37K +0.14% $17.88 1.67M Sep 20, 2024 See Footnote F2, F4
transaction ZBIO Common Stock Purchase $49.9K +2.63K +0.16% $18.97 1.67M Sep 20, 2024 See Footnote F2, F5
holding ZBIO Common Stock 161K Sep 18, 2024 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $17.50 to $18.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2 Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F3 The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $17.64 to $18.00, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F4 The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $17.70 to $18.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F5 The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $18.35 to $19.24, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.